Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 5Not yet recruiting 3Unknown 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2Fluorouracil 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1taletrectinib 1palbociclib 1eribulin 1Tomography, Optical Coherence 1Testosterone Propionate 1Testosterone 1Tamoxifen 1Tablets 1Receptors, Chimeric Antigen 1Radiotherapy 1Radiosurgery 1PF-05280014 1Ontruzant 1Ogivri 1Neoadjuvant Therapy 1Methotrexate 1Mastectomy, Segmental 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Interpersonal Psychotherapy 1Interleukin-2 1Injections 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Breast Neoplasms × Tablets × Clear all
NCT02897050 2022-04-20

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Suspended
170 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡